Palivizumab, also known as Synagis, is a monoclonal antibody injection used to prevent severe respiratory syncytial virus (RSV) infection in infants and young children. It is typically given to children with a high risk of complications from RSV infection, such as those born prematurely or with chronic lung or heart disease. Palivizumab works by targeting a protein on the surface of the virus, preventing the virus from attaching to and infecting the cells in the lungs.
Palivizumab, sold under the brand name Synagis, is a medication used to help prevent a serious respiratory illness in infants and young children called respiratory syncytial virus (RSV) infection [1, 2]. Here's a breakdown of its key features:
What is RSV Infection?
- RSV is a common respiratory virus that typically causes mild cold-like symptoms in most healthy children.
- However, for infants and young children with certain health conditions, RSV infection can be severe, leading to bronchiolitis (inflammation of small airways) or pneumonia (lung infection) requiring hospitalization [2, 3].
How Does Palivizumab Work?
- Palivizumab belongs to a class of medications called monoclonal antibodies.
- It works by specifically targeting a protein on the surface of the RSV virus. This prevents the virus from attaching and infecting the cells in the respiratory tract, thereby reducing the risk of developing RSV infection [1].
Who Can Benefit from Palivizumab?
- Palivizumab is not routinely used for all children. It's typically recommended for high-risk infants and young children under the age of 2 who have:
- Premature birth (born before 35 weeks gestation)
- Chronic lung disease (bronchopulmonary dysplasia)
- Congenital heart disease (heart defects present at birth)
- Weakened immune system due to medical conditions or medications [2, 4].
How is Palivizumab Given?
- Palivizumab is administered through a monthly intramuscular (IM) injection into a muscle during the RSV season, which typically occurs in fall, winter, and early spring in temperate climates [1].
- The number of doses needed depends on the infant's age and the duration of the RSV season in your region.
Benefits of Palivizumab:
- In high-risk infants and young children, Palivizumab can significantly reduce the risk of developing severe RSV infection requiring hospitalization [2].
Important Considerations:
- Palivizumab is a preventive medication, not a treatment for existing RSV infection.
- It can cause side effects, although they are usually mild and may include injection site reactions, fever, or wheezing [1].
- Palivizumab is an expensive medication, and insurance coverage may vary. Discuss with your doctor and insurance provider regarding coverage and cost.